(VIB) A Cross-Species Map and Humanized Mouse Model of Fcγ Receptors and FcRn

(AstraZeneca) AZD5863: a specific, potent, affinity-optimized Claudin 18.2 and CD3 binding T cell-engager that elicits low cytokine release and is capable of bystander killing

HPN328, a new T cell–activating construct for treating solid tumors

Novel TFRC humanized mouse model for drug delivery to the brain

Cell-depleting agents assessment in preclinical models

Anti-VISTA agents profiling: complementarity of BRGSF-HIS and hVISTA Knock-in as preclinical models for immunotherapies

Tumor cell line-derived xenograft subtype shapes tumor microenvironment composition in BRGSF-HIS mice

Myeloid cells' contribution is key in CRS pathophysiology induced by T-cell engagers in BRGSF-HIS model

Functional human myeloid cells in BRGSF-HIS humanized mice enable myeloid-directed therapy assessment

CD3 humanized mouse models as validated tools to assess immune-related adverse events of T-cell engagers

Translatable preclinical mouse models for assessment of T-cell engager-induced CRS

Novel FcγR humanized mouse models enabling efficacy and PK/PD of therapeutic antibodies

VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response

BRGSF-HIS: genOway’s mouse model to evaluate the pathogenesis of Staphylococcus aureus Panton-Valentine leukocidin in acute implant-associated osteomyelitis

CD28 humanized mouse model for efficacy and safety assessment of CD28-targeting therapies

Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized hCD47/hSIRPα mouse and MC38-hPD-L1-hCD47-LZ cell line

Myeloid and dendritic cells enhance therapeutics-induced cytokine release syndrome features in humanized BRGSF-HIS preclinical model

A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors

Targeting myeloid cells in the tumor microenvironment in BRGSF-HIS mice

Assessing T-cell engagers efficacy in vivo: Versatility of BRGSF-HIS mice

CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity

Expression of druggable myeloid targets in the BRGSF-HIS preclinical model

An albumin-angiotensin converting enzyme 2-based SARS-CoV-2 decoy with FcRn-driven half-life extension

Functional human myeloid compartment in BRGSF-HIS preclinical model

A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway

Assessing T-cell engagers in vivo: How BRGSF-HIS mice can help

Homeostasis of monocytes and lung interstitial macrophages is regulated by collagen domain-binding receptor LAIR1 in vivo

Challenging the predictability of preclinical models for assessment of T-cell engagers

Targeting tumor-associated myeloid cells: The new grail in immuno-oncology?

Humanization of a strategic CD3 epitope enables evaluation of clinical T-cell engagers in a fully immunocompetent in vivo model

An alternative approach to immunotherapy: A bispecific agonist

New insights to manage painful neuroma: Study of a nerve graft in rats

Relevant preclinical models to test T-cell engagers: The case of CD28

Tips for choosing the optimal preclinical model: focus on atherosclerosis and LDLR

Immunocompromised human serum albumin/human neonatal Fc receptor mouse model: A new xenograft model for efficacy studies of immunotherapies

The importance of genetic design when choosing your preclinical model: focus on preclinical models for cardiovascular disorders — a case study on BMPR2

NOTUM as alternative therapeutic approach to prevent clonal fixation and mutant expansion in patients predisposed to colorectal cancer

A human-specific modifier of cortical connectivity and circuit function

Predictive in vivo evaluation of immunotherapy efficacy: tHIS is a reliable model

CRISPR-Cas9 effectors facilitate generation of single-sex litters and sex-specific phenotypes

Immunotherapy efficacy assessment and metastases studies: tHIS model is highly permissive to engraftment

Cytokine release syndrome (CRS)

The importance of genetic design when choosing your preclinical model - A Case Study on GLP-1R

When rat models could provide optimized translatability: the case of CD89

Tumor grafts in preclinical research: Models, models, overall, who is the fittest of them all?

Deciphering high-dose IL-2 toxicity in reconstituted HIS mice

Back to the rat!

New doors to potential novel treatments for obesity

Uncoupling toxicity from therapeutic efficacy: the new challenge of immunotherapies

Degradation tag systems: a good way to SMASh your target (SMASh Part 2)

Uncoupling toxicity from therapeutic efficacy: a case study on ATOR-1015

Uncoupling efficacy from toxicity: a case study on MEDI5752

A novel preclinical and translational humanized CD3ε model to study the efficacy of T-cell engagers

Targeted protein degradation: new promises for “undruggable” diseases (SMASh Part 1)

Define “humanized”: two mouse models helping produce cancer immunotherapies

Part 5: HSA/hFcRn, a powerful model for your PK/PD studies

Part 4: Humanized immune checkpoint mouse models for immuno-oncology studies

A Knockin C3-reporter mouse model represents a valuable tool to monitor C3 levels, a biomarker of inflamed versus uninflamed tissues

Part 3: BRGSF-HIS, a new human immune system mouse model for immuno-oncology studies

Syngeneic mouse models

HSC-derived cell fate tracking

Part 2: BRGSF, a new immunodeficient model for immuno-oncology studies

A VISTA on naive T cell fate

A finely tuned crosstalk between enteric neurons and muscularis macrophages: evidence from a conditional Knockout mouse model developed by genOway

Part 1: Toward a better effective preclinical model in immuno-oncology

Prime Editing: An immature, yet already very exciting new gene editing tool

A new Nature report by Bristol-Myers Squibb provides new insights into VISTA biology and design of combination therapies

FLEx technology and optogenetics: Flipping the switch on gene expression with high spatial and temporal resolution

6 good reasons to employ our repository Knockout mouse models in your in vivo studies

Immune checkpoint inhibitors: A strategy to tackle cancer?

Unexpected genomic rearrangements at targeted loci associated with CRISPR/Cas9-mediated Knockin

Improving in vitro models: the coming of age of organoids

iPS technology: Four factors that will change the world… some day

CRISPR: A brimming toolbox but no all-in-one